J&J to discontinue trial after HIV vaccine found ineffective

Published by

(Reuters) -Johnson & Johnson said on Wednesday it will discontinue the late-stage global trial of an HIV vaccine after it was found ineffective at preventing infections. The trial involved administering two different types of a shot – that uses a cold-causing virus to deliver genetic code of HIV – spread over four vaccination visits in a year. J&J used a similar technology for its COVID-19 vaccine. Shares of J&J were down 1% at $170.57 in morning trade.The HIV vaccine study, which began in 2019, was conducted at over 50 sites and included about 3,900 men who have sex with men and transgender p…

Read More

Leave a Reply